ORIEN member cancer centers are true partners in data exchange and collaboration through the use of a common protocol, Total Cancer Care®.
M2Gen analyzes data from all participating ORIEN centers to more quickly connect patients with clinical trials based on their molecular profile. ORIEN provides the information and tools needed to study the long-term effects of disease, while assisting cancer center member institutions in their development of precision medicine.
Researchers at ORIEN member institutions access the consortium’s large, shared data warehouse to ask new research questions, develop more effective, competitive, grant submissions and participate in cross-institutional collaborations and biomarker discovery projects with academic partners and pharmaceutical companies. This rapid-learning environment allows scientists to analyze and share findings so that that research can be retested and learnings reapplied.
Located in Tampa, Moffitt Cancer Center is the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida, a distinction that recognizes excellence in research, its contributions to clinical trials, prevention and cancer control. Moffitt has made a lasting commitment to the prevention and cure of cancer, working tirelessly in the areas of patient care, research and education to advance one step further in fighting this disease. Moffitt is one of the top-ranked cancer hospitals in the nation and has been listed in U.S. News & World Report as one of the “Best Hospitals” for cancer since 1999. Moffitt treats patients from every county in Florida, every state in the United States and 100+ countries. With more than 4,500 employees, Moffitt has an economic impact on the state of nearly $1.6 billion.
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
The Ohio State University Comprehensive Cancer Center– Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) has more than 300 cancer researchers and sub-specialized cancer physicians spanning 12 of the 15 colleges at Ohio State and is one of only four centers funded by the NCI to conduct both phase I and phase II clinical trials on novel anticancer drugs. Treating more than 10,000 patients annually, the center manages hundreds of cancer clinical trials, and holds three prestigious NCI SPORE grants for the study of leukemia, thyroid cancer and sarcoma. In December 2014, The OSUCCC – James opened a transformational 21 floor, 1.1 million square foot, 306-bed cancer hospital that places cancer care operations in close proximity to the institution’s robust research facilities. Working together, clinicians and researchers at the OSUCCC – James are speeding the development and delivery of treatments that target the molecules and markers fueling each person’s unique cancer.
City of Hope is a comprehensive cancer center and independent biomedical research institution committed to curing cancer, diabetes and other life-threatening diseases. Designated as a Comprehensive Cancer Center, the highest recognition bestowed by the National Cancer Institute, City of Hope is also a founding member of the National Comprehensive Cancer Network and maintains research and treatment protocols that advance care throughout the nation.
Each year, we treat more than 7,500 new patients, including almost 2,000 who came to City of Hope for a second opinion and transferred their care to us. We conduct more than 300 clinical trials, enrolling more than 5,000 patients, including almost 600 enrolled in interventional trials. City of Hope is one of the few institutions with a genomic tumor board. Our institution also participates in the IBM Watson initiative and has joined the NCI-MATCH clinical trial. Founded more than 100 years ago, City of Hope has one of the nation’s largest and most successful stem cell transplantation programs, with outcomes that are unparalleled. Our physicians are experts in robotic-assisted urologic surgeries and also use this surgical technology to battle lung cancer, liver cancer and other life-threatening illnesses. City of Hope is consistently ranked as one of the nation’s top cancer hospitals by U.S. News & World Report.
UVA Cancer Center’s mission is to reduce the burden of cancer through care for the patients of today, and through research and education for the patients of tomorrow. Approximately 180 cancer researchers are organized around five programs and have more than $50 million in funded research annually. Clinical programs are led by physicians honored as Best Doctors in America® and Newsweek’s Top Cancer Doctors. Our cancer center is one of the first in the country to formalize a pancreatic cancer program with a high-risk clinic. We have the region’s only high-risk breast and ovarian cancer program. UVA established one of the first tumor registries in the world. UVA has been funded since 2001 for the Mid-Atlantic Division of the Cooperative Human Tissue Network. Our researchers and clinicians work diligently to understand why cancer occurs, find innovative ways to treat it and offer the most advanced cancer services in Virginia.
The University of Colorado Cancer Center (CU Cancer Center), located at the University of Colorado Anschutz Medical Campus, is Colorado’s only National Cancer Institute-designated comprehensive cancer center, a distinction recognizing its outstanding contributions to research, clinical trials, prevention and cancer control. CU Cancer Center is a consortium of approximately 400 researchers and physicians at three state universities (University of Colorado Anschutz Medical Campus, University of Colorado Boulder and Colorado State University) and three clinical institutions (University of Colorado Hospital, Children’s Hospital Colorado and Denver VA Hospital) all working toward one goal: translating science into life.
The University of New Mexico Comprehensive Cancer Center (UNM CCC) assures that all New Mexicans have access to world class cancer care and benefit from advances in clinical, transitional and basic cancer research. Our multidisciplinary teams of 116 physicians in every cancer specialty — New Mexico’s largest cancer team — work with our nurses, pharmacists and other cancer professionals to develop a specialized treatment plan for each of our 10,000 patients every year. We provide access to more than 160 cancer clinical trials through the New Mexico Cancer Care Alliance, an “exemplary national model for cancer health care delivery.” In collaboration with our scientific partners (Los Alamos and Sandia National Laboratories, Lovelace Respiratory Research Institute), our 132 scientists are supported by more than $72 million annually in research funds to develop innovative interventions that include education, prevention, novel therapies and precision medicine.
The Morehouse School of Medicine (MSM) Cancer Care & Research Community (CCRC) is made up of special people — students, scientists, clinicians, volunteers, and donors — dedicated to giving their energy, talents and unique skills to provide the best care for our patients and to discover new ways to combat this deadly disease. Our mission is to conduct laboratory, clinical, community-based participatory, and epidemiological cancer research and to better understand and reduce cancer health disparities. Our team does this by working to increase the number of highly competent cancer researchers and clinicians at our facilities, promote cancer screenings and healthy lifestyles, and expand minority participation in clinical oncology trials. CCRC has more than 50 affiliated members engaged in Cancer Immuno-biology, Drug Discovery, Clinical, Implementation Science, and Cancer Health Disparities Research.
As New Jersey’s only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey is dedicated to improving the prevention, detection, treatment, and care of patients with cancer, through the transformation of laboratory discoveries into clinical practice and precision care. Rutgers Cancer Institute delivers advanced comprehensive care to adults and children, including access to clinical trials, and conducts cutting-edge cancer research. The leadership of Rutgers Cancer Institute comprises distinguished researchers and physicians who are internationally recognized in their field. Our basic scientists, clinical researchers, and population scientists meet regularly to exchange information to ensure: that laboratory discoveries are refined and applied to clinical care as quickly as possible; that clinical observations reach laboratory researchers on a continuing basis; and that prevention strategies are interwoven in to all research programs.
USC Norris Comprehensive Cancer Center has been leading the fight to make cancer a disease of the past. As one of the original NCI-designated comprehensive cancer centers in the United States, its mission is to treat and prevent cancer by advancing and integrating education, research, and personalized patient care. For more than 40 years, USC Norris has been revolutionizing cancer research with innovative surgical techniques and novel cancer treatments and is listed as one of the nation’s best cancer hospitals in U.S. News & World Report. Discoveries and breakthroughs in cancer biology have led the way to entirely new classes of cancer treatment. USC Norris is at the cutting edge of prevention, detection, and treatment. With a multidisciplinary team of more than 250 dedicated scientists and physicians, USC Norris Comprehensive Cancer Center offers hope for patients with cancer and their families’ cancer.
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) is a not-for-profit corporation dedicated to advancing military medical research.
Authorized by the U.S. Congress to support research and education at the Uniformed Services University of the Health Sciences and throughout the armed forces, HJF serves as a vital link between the military medical community and private partners.
Our scientific, medical, management and administrative employees work throughout the U.S. and around the world. Our diverse staff supports preeminent scientific programs that benefit members of the armed forces and civilians alike.
HJF manages many types of research programs, ranging from small, bench-top projects to complex, multi-site clinical endeavors. The programs perform research across many medical disciplines, including cancer, combat casualty care, infectious disease, clinical and rehabilitative medicine, and mental health.
10902 N. McKinley Drive
Tampa, FL 33612
F (813) 384-5049